Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10028019 | International Journal of Antimicrobial Agents | 2005 | 9 Pages |
Abstract
Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500Â mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2Â g once a day and 500Â mg every 12Â h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17-0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
José Manuel Querol-Ribelles, José MarÃa TenÃas, José Manuel Querol-Borrás, Teodoro Labrador, Angel Nieto, Damiana González-Granda, Isidoro MartÃnez,